BioCentury
ARTICLE | Clinical News

Opdivo meets OS endpoint in non-squamous NSCLC study

April 18, 2015 12:53 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) stopped the Phase III CheckMate -057 trial early after an independent data monitoring committee concluded that Opdivo nivolumab met the primary endpoint of superiority to docetaxel in improving overall survival in previously-treated patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Spokesperson Carrie Fernandez would not disclose when BMS plans to seek a label extension to treat non-squamous NSCLC. The human IgG4 mAb against programmed cell death 1 ( PDCD1; PD-1; CD279) has Fast Track designation in the U.S. to treat NSCLC, renal cell carcinoma (RCC) and melanoma. ...